Lista de obras -

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

artículo científico publicado en 2012

2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis

artículo científico publicado en 2012

2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

artículo científico publicado en 2013

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative

artículo científico publicado en 2013

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus

artículo científico publicado en 2019

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

scientific article published on 05 August 2019

2020 American College of Rheumatology Guideline for the Management of Gout

artículo científico publicado en 2020

2020 American College of Rheumatology Guideline for the Management of Gout

scientific article published on 11 May 2020

A Multi-Centre Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis

scientific article published on 16 December 2019

A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria

artículo científico

A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis

scientific article published on 22 September 2020

Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial

artículo científico publicado en 2019

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials ⬇️

artículo científico publicado en 2011

Characterisation of an epigenetically altered CD4(+) CD28(+) Kir(+) T cell subset in autoimmune rheumatic diseases by multiparameter flow cytometry

artículo científico publicado en 2016

Clinical Phenotypes of Patients with Systemic Sclerosis with Distinct Molecular Signatures in Skin

artículo científico publicado en 2022

Current and future outlook on disease modification and defining low disease activity in systemic sclerosis

artículo científico publicado en 2020

Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises

artículo científico publicado en 2015

Dissecting the cellular mechanism of prostacyclin analogue iloprost in reversing vascular dysfunction in scleroderma

artículo científico publicado en 2020

Fatigue and its Association with Social Participation, Functioning and Quality of Life in Systemic Sclerosis

artículo científico publicado en 2019

Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile

artículo científico publicado en 2019

Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis

scientific article published on January 2014

Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise

artículo científico publicado en 2012

Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial

artículo científico publicado en 2017

Management of systemic sclerosis-associated interstitial lung disease in the current era

artículo científico publicado en 2020

Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)

artículo científico publicado en 2019

New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis

artículo científico publicado en 2020

Outcome evaluations in gout

artículo científico publicado en 2007

Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults with Early Diffuse Cutaneous Systemic Sclerosis

artículo científico publicado en 2020

Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities

artículo científico publicado en 2020

Predictive Significance of Serum Interferon Inducible Protein Score for Response to Treatment in Systemic Sclerosis Related Interstitial Lung Disease

artículo científico publicado en 2020

Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18

scientific article published on 01 November 2019

Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and II

artículo científico publicado en 2020

Response to: 'Riociguat in systemic sclerosis: a potential for disease modification' by Jain and Dhir

scientific article published on 15 July 2020

Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial

artículo científico publicado en 2020

Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management

artículo científico publicado en 2020

The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report

artículo científico publicado en 2010

Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II

scientific article published on 20 May 2020

Update of EULAR recommendations for the treatment of systemic sclerosis

artículo científico publicado en 2016

Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria

artículo científico publicado en 2018

Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung Disease

artículo científico publicado en 2019

Lista de obras de

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis

2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

2020 American College of Rheumatology Guideline for the Management of Gout

2020 American College of Rheumatology Guideline for the Management of Gout

A Multi-Centre Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis

A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria

A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis

Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials ⬇️

Characterisation of an epigenetically altered CD4(+) CD28(+) Kir(+) T cell subset in autoimmune rheumatic diseases by multiparameter flow cytometry

Clinical Phenotypes of Patients with Systemic Sclerosis with Distinct Molecular Signatures in Skin

Current and future outlook on disease modification and defining low disease activity in systemic sclerosis

Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises

Dissecting the cellular mechanism of prostacyclin analogue iloprost in reversing vascular dysfunction in scleroderma

Fatigue and its Association with Social Participation, Functioning and Quality of Life in Systemic Sclerosis

Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile

Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis

Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise

Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial

Management of systemic sclerosis-associated interstitial lung disease in the current era

Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)

New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis

Outcome evaluations in gout

Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults with Early Diffuse Cutaneous Systemic Sclerosis

Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities

Predictive Significance of Serum Interferon Inducible Protein Score for Response to Treatment in Systemic Sclerosis Related Interstitial Lung Disease

Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18

Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and II

Response to: 'Riociguat in systemic sclerosis: a potential for disease modification' by Jain and Dhir

Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial

Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management

The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report

Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II

Update of EULAR recommendations for the treatment of systemic sclerosis

Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria

Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung Disease